Form4insider filings, from the source

SEC Form 4 · accession 0001237899-15-000058

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
George Yancopoulos
Officer — President Regeneron Laboratori · Director
Period of report
Dec 16, 2015
Accepted (ET)
Dec 18, 2015 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockDec 16, 2015M1,921$52.03A501,921D
Common Stockholding———5,654IBy 401(k) Plan
Common Stockholding———567,976Iby Trust

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Incentive Stock Option (right to buy)F1$52.03Dec 16, 2015M1,921D—Dec 16, 2021Common Stock1,9210D
Non-Qualified Stock Option (right to buy)F2$555.67Dec 16, 2015A146,815A—Dec 16, 2025Common Stock146,815146,815D

Explanation of responses